D
The startup has developed an AI-driven drug discovery platform that utilizes machine learning algorithms to predict compound-protein binding probabilities. This technology reduces the incidence of false positives in drug screening, enabling pharmaceutical companies to accelerate the discovery process while minimizing costs and resource expenditure.
Updated 3 months ago
Funding
$630K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup has developed an AI-driven drug discovery platform that utilizes machine learning algorithms to predict compound-protein binding probabilities. This technology reduces the incidence of false positives in drug screening, enabling pharmaceutical companies to accelerate the discovery process while minimizing costs and resource expenditure.